Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-09-26
2006-09-26
Kifle, Bruck (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
07112607
ABSTRACT:
The present invention relates to compounds of formula (IA):the preparation thereof, pharmaceutical formulations thereof, and their use in medicine as allosteric adenosine receptor modulators for uses including protection against hypoxia and ischemia induced injury and treatment of adenosine-sensitive cardiac arrhythmias.
REFERENCES:
patent: 3558606 (1971-01-01), Tinney
patent: 4256755 (1981-03-01), Smith, Jr.
patent: 5026698 (1991-06-01), Fujikawa et al.
patent: 5532233 (1996-07-01), Weber et al.
patent: 5585385 (1996-12-01), Natsugari et al.
patent: 5593988 (1997-01-01), Tahara et al.
patent: 5747486 (1998-05-01), Sohda et al.
patent: 5939432 (1999-08-01), Baraldi
patent: 6046189 (2000-04-01), Sohda et al.
patent: 6143777 (2000-11-01), Jonas et al.
patent: 6177444 (2001-01-01), Baraldi
patent: 6194449 (2001-02-01), Baraldi
patent: 6323214 (2001-11-01), Baraldi
patent: 6713638 (2004-03-01), Linden et al.
patent: 2204735 (1972-08-01), None
patent: 2233457 (1973-02-01), None
patent: 2323149 (1973-11-01), None
patent: 3724031 (1998-01-01), None
patent: 407955 (1991-01-01), None
patent: 393101 (1974-05-01), None
patent: 5345785 (1993-12-01), None
patent: 50011397 (1995-04-01), None
patent: 7304755 (1995-11-01), None
patent: 8337583 (1996-12-01), None
patent: 93/07129 (1993-04-01), None
patent: 96/14319 (1996-05-01), None
patent: WO99/21617 (1999-05-01), None
WEBSTER'S Ninth New Collegiate Dictionary, (c) 1994 by Merriam-Webster Inc., p. 787.
Amemiya, Y. et. al., “Synthesis of Thromboxane Synthetase Inhibitory Activity . . . , ” J. Med. Chem., 1989, vol. 32, No. 6, pp. 1265-1272.
Bruns, R.F. et. al., Chemical Abstract, vol. 114, Abstract #220744, 1991.
Dray, A. “Inflammatory mediators of pain” Brit. J. of Anaes., 1995, vol. 75, pp. 125-131.
Corral, et al., “Reacciones de Bischlery de Friedlander Con 2-Amino-3Aroil-Tiofenoes,” Afinidad, Mar.—Apr. (1978).
Cas for Routh, et al., “Tachykinin Receptors in the Spinal Cord, Progress in Brain Research,” vol. 104, pp. 93-108.
Cas for Chesselet, et al., “Ischemic Damage in the Striatum of Adult Gerbils: Relative Sparing of Somatostatinergic and Cholinergic Interneurons Contrasts with Loss of Efferent Neurons,” Experimental Neurology, vol. 110, No. 2, pp. 209-218.
Cas for Cragg, et al., Tachykinin Antagonists in Cartoid Body Responses to Hypoxia and Substance P in the Rat, Respiration Physiology, vol. 95, No. pp. 295-310.
Cas for Benedek, et al., “Potentiation of Thermoregulatory and Analgesic Effects of Morphine by Calcium Antagonists,” Pharmacological Research Comms., vol. 16, No. 10, pp. 1009-1018.
Cas for Ghio, et., “Clinical Evaluation of Calcium-Antagonist Drugs,” J of Cardiovascular Pharmacology, vol. 20, pp. S71-74.
Cas for Zhou, et al., “Effects of Calcium Blockers on the Performance of Left and Right Ventricles During Acute Hypoxia,” Sheng Li Hseuh Pao, vol. 44, pp. 237-243.
Cas for Ueno, et al., “Simultaneous Determination of a New Dihydropyridine Calcium Blacker and its Pyridine Metabolite in Dog Plasma by Column Switching High-Performance Liquid Chromatography with Electrochemical and Ultravioletdetection,” Analytical Science.
Kollias-Baker,et al., “Allosteric Enhancer PD 81,723 ACTS by Novel Mechanism to Potentiate Cardiac Actions of Adenosine,” Cir. Research, vol. 75, No. 6, pp. 961-971 (1994).
Kollias-Baker,et al., “The Allosteric Enhancer, PD 81,723, Potentiates the Cardiac Effects of Adenosine by Enchancing the Binding of Agonists to A1 Adenosinereceptors,” A Dissertation Presented to the Graduate School of the University of Florida (1994).
Leung,et al., “Enhancement of Adenosine A1 Receptor Functions by Benzoylthiophenes in Guinea Pig Tissues In Vitro,” Archives of Pharmacology, vol. 352, No. 2, pp. 206-212.
Mizumura,et al., “PD 81,723 An Allosteric Enhancer of the A1 Adenosine Receptor, Lowers the Threshold for Ischemic Preconditioning in Dogs,” Cir. Research, vol. 79, No. 3, pp. 415-423 (Sep. 1996).
Mudumbi,et al., “Cardia Functional Responses to Adenosine by PD 81,723, An Allosteric Enhancer of the Adenosine A1 Receptor,” American Journal of Physiology,vol. 264, pp. H 1017-H1022.
Nakanishi,et al., “Studies on Pcychotropic Drugs, 18.1Synthesis and Structure-Activity Relationships of 5-Phenyl-1,3-Dihydro-2H-Thieno[2,3-E][1,4]Diazepin-2-Ones,” Journal of Medicinial Chemistry, vol. 16, No. 3, pp. 214-219, 1973.
Robba,et al., “No. 144-Thienopyrimidines. IX—Etude de la Thieno[2,3-D]Pyrimidines et de ses Derives,” Buletinede la Societe Chimique de France, pp. 761-764 (1976)-.
Amoah-Apraku,et al., “Selective Potentiation by An A1 Adenosine Receptor Enhancer of the Negative Dromotropic Action of Adenosine in the Guinea Pig Heart,” No. 2, pp. 611-617 (1993).
Bhattacharya,et al., “Effects of Long-Term Treatment With the Allosteric Ehnancer, PD 81,723, N Chinese Hamster Ovary Cells Expressing Recombinant Human A1 Adenosine Receptors,” Molecular Pharm., vol. 50, pp. 104-111 (1996).
Bhattacharya,et al., “The Allosteric Enhancer, PD 81,723, Stabilizez Human A1 Adenosine Receptor Coupling to G Proteins,” Biochimica et Biophysics ACTA, 1265: pp. 15-21, 1995.
Bruns,et al., “Allosteric Enhancement of Adenosine A1 Receptor Binding and Function by 2-Amino-3-Benzoylthiophenes,”Molecular Pharm., vol. 38, No. 6, pp. 939-949 ( 1990).
Bruns,et al., “Structure-Activity Relationships for Enhancement of Adenosine A1 Receptor Binding by 2-Amino-3-Benzoylthiophenes,”Molecular Pharm., vol. pp. 950-958 (1990).
Cao,et al., Adenosine A1 Receptor Enhancer, “PD 81,723 and Cerebral Ischemia/Reperfusion Injury in th e Gerbil,” General Pharmacology, vol. 26, No. 7, pp. 1545-1548 (1995).
Dennis,et al., “Modulation of Atrioventricular Nodal Function by Metabolic and Allosteric Regulators Endogenous Adenosine in Guinea Pig Heart,” Circulation, vol. 94, No. 10, pp. 2551-2559 (1996).
Fortea, “Thieno[2,3-D]Pyrimidine3-Oxides. Synthesis and N-Oxide Reactions of 4-Phenyl-And-4-Aminotheino[2,3-,]Pyrimidine3-Oxides,” Journal Fur Praktische Chemie, Band 317, Heft 5, p 705-711 (1975).
Hromatka, et al., Uber die Nitrierung von 7-Chlor-5-Phenyl-1H-Thieno[2,3-E]1,-4-Diazepin-2(3H)-on, Monatsheft fur Chemie, vol. 104, pp. 709-714 (1973).
Janusz,et al., “Fu nctional Activity of the Adenosine Binding Enhancer, PD 81,723, In the In Vitro Hippocampal Slice,” Brain Research, vol. 567, pp. 181-187, (1991).
Kollias-Baker,et al., “Novel Approach for Enhancing Atrioventriuclar Nodal Conduction Delay Mediated by Endogenous Adenosine,” Cir. Research, vol. 75, No. 6, pp. 972-980 (1994).
Copy of International Search Report, dated Aug. 6, 2003, issued in PCT/US02/08821 (filed Mar. 19, 2002).
Kollias-Baker, et al., Agonist-Independent Effect of an Allosteric Enhancer of the A1Adenosine Receptor in CHO Cells Stably Expressing the Recombinant Human A1 Receptor,Journal of Pharmacology and Experimental Therapeutics, 1997, 281, 761-768.
Van der Klein, et al, “Allosteric Modulation of the Adenosine A1 Receptor. Synthesis and Biological Evaluation of Novel 2-Amino-3-Benzoylthiophenes as Allosteric Enhancers of Agonist Binding,”J. Med. Chem, Aug. 1999, 42, 3629-2635.
Tinney, et al., “Synthesis and Pharmacological Evaluation of 2,3-Dihydro-1H-thieno[2,3-e][1,4]diazepines,”J. Med. Chem, 1974, 17, 624-630.
Baba, et al., “Studies on Disease-Modifying Antirheumatic Drugs. IV. Synthesis of Novel Thieno[2,3-b: 5,4-c]Dipyridine Derivatives and Their Anti-Inflammatory Effect,”Chem. Pharm. Bull., Jul. 1999, 47, Abstract.
Copy of International Search Report, dated May 28, 1999, issued in PCT/US98/20333 (filed Sep. 30, 1998).
Bruns, R.F., “Adenosine Receptors,”Ann. N.Y. Acad. Sci. 1990, 603, 211-226.
Dave, K.G. et al., “Reaction of Nitriles under Acidic Conditions . . . ,
Jones Day
Kifle Bruck
King Pharmaceuticals Research & Development, Inc.
Kukkola Paivi
LandOfFree
Allosteric adenosine receptor modulators does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Allosteric adenosine receptor modulators, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Allosteric adenosine receptor modulators will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3579943